Biovista’s repositioned drug candidate BVA201 targeting Multiple Sclerosis (MS) is ready for Proof of Concept (PoC) studies in man.
Two more candidates, BVA202 and BVA203 targeting rare diseases (Friedreich’s Ataxia and Leber’s Hereditary Optic Neuropathy (LHON) respectively) are at an advanced pre-clinical stage and are expected to go into PoC in man in the near term.
Our pipeline strategy focuses on repositioned drugs with a known safety profile that can enter PoC and rapidly thereafter the Phase IIa/b stage, once efficacy in the selected indication is demonstrated.
Biovista is currently developing additional repositioned candidates in areas such as epilepsy and oncology.
We are open to licensing or other partnering discussions with biopharma, generics and OTC manufacturers.